MX2015011678A - Inhibidores de leucotrieno a4 hidrolasa. - Google Patents
Inhibidores de leucotrieno a4 hidrolasa.Info
- Publication number
- MX2015011678A MX2015011678A MX2015011678A MX2015011678A MX2015011678A MX 2015011678 A MX2015011678 A MX 2015011678A MX 2015011678 A MX2015011678 A MX 2015011678A MX 2015011678 A MX2015011678 A MX 2015011678A MX 2015011678 A MX2015011678 A MX 2015011678A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- solar
- solar panel
- exemplary embodiments
- accordance
- Prior art date
Links
- 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 title abstract 3
- 108010072713 leukotriene A4 hydrolase Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 8
- 238000000034 method Methods 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 230000001668 ameliorated effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000000903 blocking effect Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361781193P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/027428 WO2014152518A2 (en) | 2013-03-14 | 2014-03-14 | Inhibitors of leukotriene a4 hydrolase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015011678A true MX2015011678A (es) | 2016-07-08 |
Family
ID=51581716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011678A MX2015011678A (es) | 2013-03-14 | 2014-03-14 | Inhibidores de leucotrieno a4 hidrolasa. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9777006B2 (enExample) |
| EP (1) | EP2970309A4 (enExample) |
| JP (1) | JP6534650B2 (enExample) |
| KR (1) | KR20150127246A (enExample) |
| AU (1) | AU2014239567B2 (enExample) |
| BR (1) | BR112015022864A8 (enExample) |
| CA (1) | CA2906084A1 (enExample) |
| MX (1) | MX2015011678A (enExample) |
| RU (1) | RU2678196C2 (enExample) |
| WO (1) | WO2014152518A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2614090T3 (es) | 2005-12-29 | 2017-05-29 | Celtaxsys, Inc. | Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa |
| WO2014164658A1 (en) | 2013-03-12 | 2014-10-09 | Celtaxsys, Inc. | Methods of inhibiting leukotriene a4 hydrolase |
| JP6562898B2 (ja) | 2013-03-14 | 2019-08-21 | セルタクシス，インコーポレイテッド | ロイコトリエンａ４加水分解酵素の阻害剤 |
| KR20150127245A (ko) * | 2013-03-14 | 2015-11-16 | 켈탁시스, 인코퍼레이티드 | 류코트라이엔 a4 가수분해효소의 저해제 |
| CN104530152A (zh) * | 2015-01-15 | 2015-04-22 | 佛山市赛维斯医药科技有限公司 | 一种含丙烯腈基和三氟甲氧苯基o-葡萄糖苷结构化合物及用途 |
| CN104530151A (zh) * | 2015-01-15 | 2015-04-22 | 佛山市赛维斯医药科技有限公司 | 一种含硝基苯s-葡萄糖苷结构的化合物及其用途 |
| CN104530153A (zh) * | 2015-01-15 | 2015-04-22 | 佛山市赛维斯医药科技有限公司 | 一类苯基s-葡萄糖苷衍生物、其制备方法和在医药上的用途 |
| US10385007B2 (en) | 2016-12-09 | 2019-08-20 | Celtaxsys, Inc. | Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase |
| US11498903B2 (en) | 2017-08-17 | 2022-11-15 | Bristol-Myers Squibb Company | 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases |
| SG11202010115RA (en) | 2018-05-15 | 2020-11-27 | Alkahest Inc | Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase |
| CA3102077A1 (en) | 2018-05-31 | 2019-12-05 | Sanjeev AHUJA | Method of reducing pulmonary exacerbations in respiratory disease patients |
| CN112996790B (zh) | 2018-10-30 | 2023-11-03 | 克洛诺斯生物公司 | 用于调节cdk9活性的化合物、组合物和方法 |
| CA3185469A1 (en) | 2020-08-14 | 2022-02-17 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
| CA3221177A1 (en) | 2021-11-01 | 2023-05-04 | Meghan Kerrisk Campbell | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6815872A (enExample) | 1967-11-22 | 1969-05-27 | ||
| JPS5614663B2 (enExample) | 1971-08-21 | 1981-04-06 | ||
| US4582833A (en) | 1984-04-16 | 1986-04-15 | American Cyanamid Company | 2-(substituted-1-piperazinyl)[1,2,4]triazolo[1,5-a]pyrimidines |
| US4576943A (en) | 1984-10-09 | 1986-03-18 | American Cyanamid Company | Pyrazolo[1,5-a]pyrimidines |
| US5308852A (en) | 1992-06-29 | 1994-05-03 | Merck Frosst Canada, Inc. | Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis |
| US6506876B1 (en) | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| WO1997029774A1 (en) | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor |
| US5952349A (en) | 1996-07-10 | 1999-09-14 | Schering Corporation | Muscarinic antagonists for treating memory loss |
| US6309561B1 (en) | 1997-12-24 | 2001-10-30 | 3M Innovative Properties Company | Liquid crystal compounds having a chiral fluorinated terminal portion |
| US6380203B1 (en) * | 1998-01-14 | 2002-04-30 | Merck & Co., Inc. | Angiogenesis inhibitors |
| GB9815880D0 (en) | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| AR023659A1 (es) | 1998-09-18 | 2002-09-04 | Vertex Pharma | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos |
| US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| US6924313B1 (en) | 1999-09-23 | 2005-08-02 | Pfizer Inc. | Substituted tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
| AU2001234420A1 (en) | 2000-02-03 | 2001-08-14 | Eli Lilly And Company | Potentiators of glutamate receptors |
| US6552023B2 (en) | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
| JP2001354657A (ja) | 2000-06-09 | 2001-12-25 | Sds Biotech:Kk | 置換ピペラジン誘導体及び農園芸用殺菌剤 |
| US6875483B2 (en) | 2000-07-06 | 2005-04-05 | Fuji Photo Film Co., Ltd. | Liquid crystal composition comprising liquid crystal molecules and alignment promoter |
| WO2002064211A1 (en) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Thrombin inhibitors |
| EP1372655B1 (en) | 2001-03-02 | 2008-10-01 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
| AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| FR2826011B1 (fr) | 2001-06-14 | 2004-12-10 | Oreal | Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique |
| SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| EP1435946B8 (en) | 2001-09-14 | 2013-12-18 | Amgen Inc. | Linked biaryl compounds |
| AU2002363236A1 (en) | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| CA2502359A1 (en) | 2002-10-17 | 2004-04-29 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction |
| US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| US20040198777A1 (en) | 2002-12-20 | 2004-10-07 | Mitokor, Inc. | Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto |
| JPWO2004089410A1 (ja) | 2003-04-03 | 2006-07-06 | 協和醗酵工業株式会社 | 神経因性疼痛の予防及び／または治療剤 |
| WO2004099164A1 (en) | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection |
| JP2005008581A (ja) * | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| DE602004016002D1 (de) | 2003-07-28 | 2008-10-02 | Janssen Pharmaceutica Nv | Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren |
| CA2539276A1 (en) | 2003-09-17 | 2005-03-31 | Decode Genetics Ehf. | Methods of preventing or treating recurrence of myocardial infarction |
| DE10356579A1 (de) * | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | Aminderivate |
| SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
| WO2005075479A1 (en) | 2004-02-04 | 2005-08-18 | Neurosearch A/S | Dimeric azacyclic compounds and their use |
| WO2006033795A2 (en) * | 2004-09-17 | 2006-03-30 | Wyeth | Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth |
| CN101189012A (zh) | 2005-03-31 | 2008-05-28 | 詹森药业有限公司 | 苯基和吡啶基lta4h调节剂 |
| GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| EP1926708B1 (en) | 2005-09-21 | 2014-06-18 | Decode Genetics EHF | Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation |
| CN1947717B (zh) | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
| DE102005049954A1 (de) | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
| ES2614090T3 (es) | 2005-12-29 | 2017-05-29 | Celtaxsys, Inc. | Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa |
| CN102633783A (zh) | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| WO2008016131A1 (en) * | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| AU2007312389B2 (en) | 2006-10-19 | 2012-02-23 | F. Hoffmann-La Roche Ag | Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors |
| HUE032761T2 (en) | 2006-12-14 | 2017-10-30 | Janssen Pharmaceutica Nv | Process for the preparation of piperazinyl and diazepanylbenzamide derivatives |
| FR2911140B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| FR2911139A1 (fr) | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| FR2911138B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| ATE540942T1 (de) | 2007-07-02 | 2012-01-15 | Hoffmann La Roche | Imidazolderivate als ccr2-rezeptor-antagonisten |
| EA201000958A1 (ru) | 2007-12-12 | 2010-12-30 | Астразенека Аб | Пептидилнитрилы и их применение в качестве ингибиторов дипептидилпептидазы i |
| MX2010009416A (es) * | 2008-02-26 | 2010-09-24 | Novartis Ag | Compuestos heterociclicos como inhibidores de cxcr2. |
| US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| WO2010011912A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Trpv4 antagonists |
| CN102030700B (zh) | 2009-09-30 | 2016-06-01 | 中国医学科学院药物研究所 | 苯甲酰胺基羧酸类化合物及其制法和药物用途 |
| WO2011053706A1 (en) | 2009-10-30 | 2011-05-05 | Janssen Pharmaceutica Nv | 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators |
| SG181109A1 (en) | 2009-12-07 | 2012-07-30 | Targacept Inc | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands |
| PT2598483T (pt) | 2010-07-29 | 2020-10-12 | Rigel Pharmaceuticals Inc | Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos |
| US8609669B2 (en) * | 2010-11-16 | 2013-12-17 | Abbvie Inc. | Potassium channel modulators |
| PH12013501882A1 (en) | 2011-03-15 | 2013-10-14 | Rib X Pharmaceuticals Inc | Antimicrobial agents |
| CA2837079A1 (en) | 2011-05-23 | 2012-11-29 | Janssen Pharmaceutica Nv | Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists |
| CN103159742B (zh) | 2011-12-16 | 2015-08-12 | 北京韩美药品有限公司 | 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用 |
| US9006235B2 (en) * | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2014164658A1 (en) | 2013-03-12 | 2014-10-09 | Celtaxsys, Inc. | Methods of inhibiting leukotriene a4 hydrolase |
| KR20150127245A (ko) | 2013-03-14 | 2015-11-16 | 켈탁시스, 인코퍼레이티드 | 류코트라이엔 a4 가수분해효소의 저해제 |
| JP6562898B2 (ja) | 2013-03-14 | 2019-08-21 | セルタクシス，インコーポレイテッド | ロイコトリエンａ４加水分解酵素の阻害剤 |
-
2014
- 2014-03-14 MX MX2015011678A patent/MX2015011678A/es unknown
- 2014-03-14 WO PCT/US2014/027428 patent/WO2014152518A2/en not_active Ceased
- 2014-03-14 BR BR112015022864A patent/BR112015022864A8/pt not_active Application Discontinuation
- 2014-03-14 AU AU2014239567A patent/AU2014239567B2/en not_active Ceased
- 2014-03-14 RU RU2015137975A patent/RU2678196C2/ru not_active IP Right Cessation
- 2014-03-14 JP JP2016502433A patent/JP6534650B2/ja active Active
- 2014-03-14 EP EP14769747.8A patent/EP2970309A4/en not_active Withdrawn
- 2014-03-14 CA CA2906084A patent/CA2906084A1/en not_active Abandoned
- 2014-03-14 KR KR1020157028772A patent/KR20150127246A/ko not_active Ceased
-
2015
- 2015-09-10 US US14/849,825 patent/US9777006B2/en not_active Expired - Fee Related
-
2017
- 2017-09-14 US US15/704,199 patent/US10399986B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US10399986B2 (en) | 2019-09-03 |
| US9777006B2 (en) | 2017-10-03 |
| BR112015022864A2 (pt) | 2017-07-18 |
| CA2906084A1 (en) | 2014-09-25 |
| RU2678196C2 (ru) | 2019-01-24 |
| BR112015022864A8 (pt) | 2019-11-26 |
| WO2014152518A2 (en) | 2014-09-25 |
| EP2970309A2 (en) | 2016-01-20 |
| US20180127424A1 (en) | 2018-05-10 |
| AU2014239567A1 (en) | 2015-10-01 |
| JP2016513696A (ja) | 2016-05-16 |
| AU2014239567B2 (en) | 2017-12-14 |
| RU2015137975A3 (enExample) | 2018-03-26 |
| JP6534650B2 (ja) | 2019-06-26 |
| US20160068534A1 (en) | 2016-03-10 |
| EP2970309A4 (en) | 2016-11-09 |
| KR20150127246A (ko) | 2015-11-16 |
| RU2015137975A (ru) | 2017-04-28 |
| WO2014152518A3 (en) | 2014-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015011678A (es) | Inhibidores de leucotrieno a4 hidrolasa. | |
| EP3183843A4 (en) | System and method to detect domain generation algorithm malware and systems infected by such malware | |
| BR112013026603A2 (pt) | sistema de monitoramento e coleta de dados remoto com análise de multicamadas | |
| GB2519882A (en) | Identifying whether an application is malicious | |
| PH12012501304A1 (en) | Device for identifying oral conditions | |
| IN2014CN04256A (enExample) | ||
| EP3044718A4 (en) | Systems and methods for using event-correlation graphs to detect attacks on computing systems | |
| BR112014013936A2 (pt) | sistema e método para contabilidade de distorção eletromagnética (em) com sistema de rastreamento em | |
| EP2971139A4 (en) | SYSTEMS AND METHOD FOR PROVIDING THE CHANGE OF A GENOMIC COPY NUMBER | |
| FR3005436B1 (fr) | Procede et dispositif de protection securitaire d'un document officiel et document officiel ainsi protege | |
| BRPI1007839A2 (pt) | métodos e sistemas de detecção de curto-circuito. | |
| FI20125761A7 (fi) | Menetelmä ja laite datakehysmyrskyjen lähteiden ilmaisemiseksi | |
| EP2859635A4 (en) | METHOD FOR IDENTIFYING DEFECTS BY MEANS OF DIFFERENTIAL PROTECTION AND DEVICE THEREFOR | |
| GB2523516A (en) | Detecting device installation and removal on a port | |
| MX370221B (es) | Quemador con monitoreo. | |
| IN2014MU00871A (enExample) | ||
| MX2015012251A (es) | Sistemas para detectar e identificar formacion de arco electrico. | |
| FR3010534B1 (fr) | Systeme et procede de detection de rayonnements neutron, gamma et muon avec des scintillateurs plastiques contigus | |
| MX2016003002A (es) | Metodos para determinar la respuesta a la terapia. | |
| MX377783B (es) | Revestimiento del sistema de fijacion para permitir una barrera de aislamiento continua en el exterior. | |
| EP2981854A4 (en) | Method and system for nowcasting precipitation based on probability distributions | |
| MX2015009040A (es) | Mitigacion de picos de energia. | |
| BR112016026195A2 (pt) | método para identificar programa malicioso potencial, sistema para identificar atividade maliciosa e meio de armazenamento legível por computador | |
| GB2495831B (en) | Protecting electronic devices from electrical supply disturbances | |
| EP2984719A4 (en) | METHOD FOR DETECTING ERRORS AND CURRENT DIFFERENTIAL PROTECTION SYSTEM THEREWITH |